About Exosome complex component RRP4
Exosome complex component RRP4 (EXOSC2) is a protein
from Homo sapiens identified by UniProt accession
Q13868, 293 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | Exosome complex component RRP4 |
|---|
| UniProt accession | Q13868 |
|---|
| Gene | EXOSC2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 293 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (44)
Diseases linked to this target (Open Targets).
- retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome · score 0.66
- neurodegenerative disease · score 0.52
- Neurodevelopmental delay · score 0.12
- breast adenocarcinoma · score 0.10
- Red cell distribution width · score 0.09
- mean platelet volume · score 0.06
- lymphocyte count · score 0.05
- platelet count · score 0.05
- leukocyte count · score 0.05
- multiple myeloma · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13868-F1 | alphafold | PREDICTED | 81.23 | — |
Amino-acid sequence (293 residues)
MAMEMRLPVA RKPLSERLGR DTKKHLVVPG DTITTDTGFM RGHGTYMGEE KLIASVAGSV ERVNKLICVK ALKTRYIGEV GDIVVGRITE VQQKRWKVET NSRLDSVLLL SSMNLPGGEL RRRSAEDELA MRGFLQEGDL ISAEVQAVFS DGAVSLHTRS LKYGKLGQGV LVQVSPSLVK RQKTHFHDLP CGASVILGNN GFIWIYPTPE HKEEEAGGFI ANLEPVSLAD REVISRLRNC IISLVTQRMM LYDTSILYCY EASLPHQIKD ILKPEIMEEI VMETRQRLLE QEG
Explore Exosome complex component RRP4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets